USPTO serial 97610360
FRESENIUS
Reviewed by CopyMark Law Group
Status 734Notice of Allowance
- Filing date
- Status date
- Registration date
- —
- Examiner
- NANNEY, KATHERINE N
- Law office
- INTENT TO USE SECTION
What this means
The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.
Need help with FRESENIUS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $349*
Plus Government fees of $300
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Scott D. Woldow
Scott D. Woldow SMITH, GAMBRELL & RUSSELL, LLP1055 THOMAS JEFFERSON ST, NW, SUITE 400WASHINGTON, DC 20007United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations in the nature of nutrition for parenteral feeding, namely, food for enteral feeding, dietetic food adapted for medical use; nutritional food admixtures and compounded nutrition for medical purposes of parenteral nutrition in the nature of natural food extracts derived from fish, meat and vegetables; intravenous fluids, namely, parenteral nutritional compounds used to treat or prevent malnutrition, undernutrition covering the needs of a patient either completely or partly; pharmaceutical preparations, namely, constituents of individual compounded pharmaceutical preparations for use in cancer therapy, infectious diseases, immune therapy, anesthesia and pain therapy as well as critical care therapies requiring individual dosing; Pharmaceutical preparations, namely, drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; Standard infusion solutions for fluid, electrolyte and energy supply for reconstitution and delivery of drugs and pharmaceutical preparations; infusion solutions for blood volume replacement and treatment of hypovolemia; pharmaceutical preparations, namely, medicated rinsing solutions for washing purposes, blood volume expanders, anti-infectives, analgesics and anesthetics; injectable critical care drugs, namely, parenterally administered pharmaceutical preparations for the therapy of critically ill states, namely, for the treatment of cardiovascular conditions, for use as diuretics, immune therapies, anticoagulants, cerebrovascular therapies, gastrointestinal therapies and hormone therapies; injectable critical care and peri-operative pharmaceuticals for the treatment of allergic reactions; intravenous drugs for infusion therapy, namely, intravenous drugs in the nature of intravenous critical care and peri-operative fluids used for rehydration, nutrition, electrolyte replenishment and the delivery of pharmaceutical preparations, intravenous critical care and peri-operative formulations used for artificial plasma volume maintenance, replacement and expansion; Oral drugs, namely, anti-infectives, analgesics and anesthetics; pharmaceutical preparations for the treatment of chronic kidney disease; pharmaceutical preparations used in oncology; urology irrigation solutions; sanitary preparations for medical purposes; dietetic substances adapted for medical use, namely, food for medically restricted diets, food for diabetics; Food supplements; Meal replacement drink mixes adapted for medical use; meal replacement powders adapted for medical use; nutritional supplements in pediatrics; clinical medical solutions for processing human blood for use in blood transfusions stored in bags; blood processing disposables, namely, processing solutions for storage and washing blood for medical purposes; blood processing accessories, namely, processing solutions for storage and washing blood for medical purposes; pharmaceutical preparations, namely, biosimilars for immunological conditions and oncological conditions; pharmaceutical preparations, namely, biosimilars used for the treatment of cancer; pharmaceutical preparations and biosimilars used for the treatment of breast and gastric disorders and diseases; biosimilar medicines, namely, immunomodulators and anticancer agents, antibodies, antibody fragments, checkpoint inhibitors and checkpoint modifiers | ACTIVE | — |
| 010 | Surgical and medical instruments and apparatus, namely, enteral feeding tubes, enteral feeding pumps, enteral giving sets for administration of enteral feeding; Programmable medical devices for global and interactive management of mono-and multi-channel infusion; infusion medical device, namely, medical machine for capturing and processing infusion data; medical devices, namely, infusion data monitors, namely, a multi-channel infusion monitor for critical care for analyzing, programming and monitoring infusion information; patient infusion monitoring sensors and alarms; monitoring sensors and alarms to be used on a person while receiving infusion therapy; medical appliances and instruments comprising infusion pumps, blood transfer devices, namely, syringe pumps for medical purposes, volumetric pumps, disposable blood collection bags for medical purposes sold empty, infusion bottles, infusion pumps and tubes; medical devices, namely, infusion apparatus racks for concentration and maintenance of the main supply and infusion configuration consisting of a medical rack for organizing medical infusion instruments; Surgical and medical apparatus and instruments, namely, infusion sets and infusion and injection devices for administering drugs; surgical and medical instruments and apparatus, namely, blood, platelet, plasma transfusion apparatus; Surgical and medical apparatus and instruments, namely, medicinal measurement medical instruments as well as parts of the aforementioned goods to measure medicine dosage, hydration, nutrition, blood volume, physiological and cardiovascular parameters and parts and fittings thereof; medical diagnostic apparatus, analytical apparatus for measuring infusion effectiveness and blood volume measuring apparatus; Medical equipment accessories used as parts of infusion apparatus, namely, clamps, tubing connectors for infusion, syringes for medical purposes, joints for syringes for medical purposes, infusion adapters, intravenous bags sold empty for intravenous therapy, cannulas, catheters, needles for medical use; Surgical and medical apparatus and instruments, namely, connectors for infusion sets and cannulas and tubes for infusion systems; Surgical and medical apparatus and instruments, namely, implantable subcutaneous catheters with infusion chamber; medical device, namely, cannulae for continuous drug application subcutaneous; medical equipment accessories, namely, cannulas for port puncturing and implantable pumps; surgical and medical instruments and apparatus, namely, introducer sets used in connection with the implantation of port systems, namely, introducer instruments for use in general surgery, local tumor surgery, chemotherapy, long-term infusion therapy, parenteral nutrition, chronic pain, and in cases of peripheral vein conditions in association with numerous blood withdrawals; medical infusion pumps and feeding tubes to administer parenteral drugs and parenteral nutrition solutions and parts therefor, namely, clamps, tubing connectors for infusion, syringes for medical purposes, joints for syringes for medical purposes, infusion adapters, intravenous bags sold empty for intravenous therapy, cannulas, catheters, needles for medical use; medical and surgical equipment and disposable equipment for use in pharmaceutical compounding of parenteral nutrition and intravenous drugs, namely, medical packaging sets comprised of disposable infusion bags, parenteral nutrition bags and intravenous drug bags sold empty and parenteral nutrition, infusion and intravenous drug bottles sold empty and parts thereof; medical packaging comprised of medical bags for blood collection, infusion, intravenous drugs, parenteral nutrition sold empty and bottles for administering medication, parenteral nutrition, infusion, and intravenous drugs sold empty as well as their parts and accessories; safety catheters; Surgical and medical apparatus and instruments, namely, automatic blood and blood component processing system for diagnostic medical use; surgical and medical apparatus and instruments, namely, blood collection, mixing and weighing system for surgical and medical use; surgical and medical apparatus and instruments, namely, medical procedure couches for donation of blood, plasma, platelet and apheresis; surgical and medical apparatus and instruments, namely, sterile connecting docking device for sterile PVC connections and their disposables; surgical and medical instruments and apparatus, namely, seals for medical tubes; surgical and medical instruments and apparatus, namely, tube sealing device with portable sealer with high capacity battery; blood processing equipment, for medical and surgical use, namely, whole blood cooling, transport and storage containers; medical devices, namely, hemoglobin screening technology used for measuring hemoglobin out of human whole blood and its disposable accessories, namely, disposable cuvettes for single use; medical equipment for blood processing, namely, automatic system for platelet concentrates agitation for medical and surgical use; Medical devices for blood processing, namely, disposable blood bag systems for collection and processing of whole blood, umbilical cord blood for medical and surgical use; blood processing disposable devices, namely, disposable transfer bag systems sold empty for processing and administration of blood components for medical and surgical use; blood processing disposable devices, namely, disposable whole blood and Red cell concentrate in-line filtration sold empty for flexible and individual processing for medical use; blood processing disposable devices, namely, disposable conventional filter systems for leukodepletion and reduction of microaggregates from blood components for medical use; blood processing disposable devices, namely, cryopreservation system comprised of bags sold empty, tubes, bags and connector sealers and parts therefore for medical and surgical use; surgical and medical instruments and apparatus, namely, blood cell separator; medical devices, namely, apheresis system, namely, separation chamber; surgical and medical apparatus and instruments, namely, autotransfusion device for use in autotransfusion procedures; disposable devices used in autotransfusion, namely, separation chamber for medical and surgical use; Dialyzers; dialysis machines; Tubes for enteral feeding; enteral feeding pumps; medical packing sets comprised of bags, bottles, structural and replacement parts filled with pharmaceutical preparations or dietetic products, namely, foods, nutritional beverages, infusions for enteral and parenteral nutrition | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 24, 2026 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Aug 24, 2026 | EX5G | SOU EXTENSION 5 GRANTED | — |
| Aug 24, 2026 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Jul 13, 2026 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jul 12, 2026 | EXT5 | SOU EXTENSION 5 FILED | — |
| May 14, 2026 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Feb 6, 2026 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Feb 6, 2026 | EXT4 | SOU EXTENSION 4 FILED | — |
| Feb 6, 2026 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Aug 11, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Aug 11, 2025 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Aug 11, 2025 | EXT3 | SOU EXTENSION 3 FILED | — |
| Aug 11, 2025 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Feb 11, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Feb 11, 2025 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Feb 11, 2025 | EXT2 | SOU EXTENSION 2 FILED | — |
| Feb 11, 2025 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Nov 17, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Nov 17, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 31, 2024 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jul 31, 2024 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Jul 31, 2024 | EXT1 | SOU EXTENSION 1 FILED | — |
| Jul 31, 2024 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Feb 13, 2024 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Dec 19, 2023 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Dec 19, 2023 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Nov 29, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Nov 9, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Oct 14, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 13, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 13, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 26, 2023 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 26, 2023 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 26, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 13, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 18, 2022 | MDSC | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Oct 15, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Oct 1, 2022 | NWAP | NEW APPLICATION ENTERED | — |